Nicholas Piramal roles out its R&D expansion plans

Nicholas Piramal India Limited, have rolled out their R&D expansion plans by inviting two internationally renowned scientists, Sir Ravinder Maini and Prof Bob Chaudhuri, to join their Scientific Advisory Board.

Mumbai(PRWEB) October 3, 2003: Nicholas Piramal India Limited, the second largest pharmaceutical company in the country, have rolled out their R&D expansion plans by inviting two internationally renowned scientists, Sir Ravinder Maini and Prof Bob Chaudhuri, to join their Scientific Advisory Board.

Speaking at the scientific review Dr. Swati Piramal, Director, Strategic Alliances & Communication, said We are investing Rs. 75 crore over the next two years and Rs. 40 crore per annum subsequently as a part of the expansion plan for the R&D center. The new R&D facility in Goregaon, Mumbai, is spread over an area of 2,00,000 sq ft and will focus on Rheumatology & Cancer research, apart from new chemical entities (NCEs) and new drug-delivery systems (NDDS)".

According to Dr. Somesh Sharma, Chief Scientific Officer, NPIL, The inclusion of eminent scientist like Sir Ravinder Maini and Prof Bob Chaudhuri will add a lot of impetus to our efforts at the R&D center." The close collaboration between eminent academic researchers, scientists and doctors in a stimulating environment will lead to major discoveries and improvements in treatment for patients," he added.

Nicholas Piramals aim is to be an integrated pharmaceutical company with a commitment to discovery, development, manufacture and marketing of indigenous pharmaceutical products. With this target in mind, the company places a premium on promoting new concepts and individual inspiration from all sources - external and internal.

NPIL is also investing in conducting clinical trials as they are cheaper and faster in India than those in developed countries with manpower costs a third of western levels. This presents another attractive opportunity that India can leverage with its access to huge patient databases and its lower cost of data management of clinical trials. The R&D program is divided into four strategic business units with different cross-functional teams that enable effective project management and a sharing of skills.

Sir Ravinder Maini, is the recipient of the prestigious Albert Lasker Award - 2003, for Clinical Medial Research and pioneering radically new and better treatments for rheumatoid arthritis - a progressive, painful and crippling disease that effects many millions of people globally. The therapy he developed has brought relief and vitality to hundreds of thousands of people worldwide, and promises to better the lives of even more individuals as it proves effective in additional debilitating illnesses.

The Lasker Awards for basic clinical and medical research have come to be known as 'America's Nobels' and 66 recipients of the Lasker award have gone on to receive Nobel prizes. They were first awarded in 1946.

For the same research Sir Maini has been honored with a Knighthood from the Queen and the Crafoord Prize from the Royal Swedish Academy of Science. Until recently Prof Maini was director of the Kennedy Rheumatology Research Institute in London. Honorary member of innumerable International societies, committees and advisory boards, Sir Maini has more than 400 articles to his credit in refereed journals and invited reviews mainly on autoimmune disease.

Professor Bob Chaudhuri, with wide research interests in Molecular basis of cancer and Neuro degenerative diseases, was until recently a Senior Research Manager at Novartis, Basel, Switzerland. As a scientist he specialised in molecular/cell biology, bio chemistry, protein chemistry, enzymology, yeast/Drosophila genetics and organic chemistry. He also has wide experience in areas of biotechnology related to the discovery and validation of new pharmaceutical entities using novel technologies. Educated as an Organic Chemist in IIT-Kanpur (PhD), MIT/Utah State University-USA (post-doc), Prof Bob Chaudhuri is currently with the School of Pharmacy at De Montfort University as a Professor of Cancer Studies.

Nicholas Piramal India Limited
Nicholas Piramal India Limited (NPIL) is India's second largest Pharmaceutical and Healthcare company. NPIL is a leader in the Cardio-vascular segment, and has a strong presence in Antibiotics and Respiratory segments, Pain management, Neuro-psychiatry and Anti-Diabetics segments. In 2001-02 its revenues stood at Rs 11.4 billion and PAT at Rs 1.18 billion.
NPIL is part of the Rs. 2500 crore (US $ 500 million) Piramal Enterprises (PEL), one of India's largest diversified business houses with interests in Retailing, Textiles, Auto-components and Engineering. The Group is headed by Mr. Ajay Piramal, who is also the Chairman of NPIL.
###